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Abstracts S7We found that despite having similar levels of spirometric impairment COPD
patients with an EFL75% of the visits had a significantly worse exacerbation
history and a much higher percentage of frequent exacerbators than those
without EFL. In GOLD stage 2 those with frequent flow limitation had a
considerably higher exacerbation history while there was little difference
between the non-EFL and those with EFL<75% of the visits. The presence of
EFL at rest may be a useful way to identify patients at greater risk of these
events.
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Introduction: The Clinical COPD Questionnaire (CCQ) measures health status
and can be used to assess health-related quality of life (HRQL). We investi-
gated whether CCQ is also associated with mortality.
Methods: Some 1111 Swedish primary and secondary care COPD patients
were randomly selected. Information from questionnaires and medical re-
cord review were obtained in 970 patients. The Swedish Board of Health
and Welfare provided mortality data. Cox regression estimated survival
with adjustment for age, sex, heart disease, and lung function (for a subset
with spirometry data, nZ530). Age and sex-standardized mortality ratios
(SMR) were calculated.
Results:Overfive years, 220patients (22.7%) died.Mortality riskwashigher for
mean CCQ3 (37.8% died) comparedwithmean CCQ<1 (11.4%); producing an
adjusted HR (and 95% CI) of 3.13 (1.98 to 4.95). After further adjustment for
FEV1%pred, the association remained (HR 2.94 (1.42 to 6.10)). The mortality
risk was higher than in the general population (SMR (and 95% CI) 1.87 (1.18
to 2.80)) with CCQ <1, increasing to 6.05 (4.94 to 7.44) with CCQ 3).
Conclusion: CCQ is predictive of mortality in COPD patients. As HRQL and
mortality are both important clinical endpoints, CCQ could be used to target
interventions.
